X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, the combined company will advance the development of first-in-class tRNA-based therapeutics to target genetic disease and cancer.
Lead Product(s): tRNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: 4SR Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2023
Details:
hC Bio’s innovations in precision protein editing therapies target genetically-defined diseases including cancer. A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
Lead Product(s): Engineered tRNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Taiho Ventures
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 04, 2022
Details:
hC Bio is simultaneously developing a second tRNA-based platform called SWTX (“Switch”) to target diseases caused by missense mutations. This technology is designed to correct for such mutations in proteins that cause disease.
Lead Product(s): tRNA-based Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
